Hims & Hers Health closed Tuesday at $28.70, down 5.7% on the week, and the story this week is one of gradual short covering running against a still-elevated bearish base ahead of a November earnings print.
Short sellers have been trimming, but the position remains substantial. At 24.2% of the free float, short interest is among the higher readings in the healthcare services sector. The direction is unambiguously lower: short interest has fallen roughly 11% over the past month, shaving around 8 million shares from peak levels seen in mid-August. The past week alone saw a further 4% reduction. Yet coverage has been orderly rather than urgent. Cost to borrow has drifted down to 0.53% from above 0.80% six weeks ago, a notably low rate for a name this heavily shorted, which tells you there is no squeeze pressure forcing anyone's hand. Availability, at 55%, is well off its 52-week trough of 0% and consistent with a borrow market that remains accessible for new shorts who want in. The ORTEX short score of 71.7 sits at the lower end of its recent range but still reflects a stock the data characterises as carrying meaningful short-side conviction.
Options are not adding much drama. The put/call ratio of 0.55 is almost exactly in line with its 20-day average and a fraction below flat on a z-score basis, placing it near the 52-week low end of defensive positioning. Call-side interest is keeping the ratio suppressed despite the week's price weakness. That combination, shorts trimming and options traders leaning long, suggests that the bears who remain are comfortable holding rather than adding, while the bulls are not yet stepping back.
The Street has landed squarely in the middle. The consensus sits at hold across 11 analysts, with a mean price target of $31.15, roughly 9% above current levels. The post-Q2 reaction was instructive: after the August earnings print, most houses raised targets but kept neutral ratings, acknowledging the revenue acceleration (Q2 revenue up 38% year-on-year to $753 million, subscribers reaching 2.9 million) while stopping short of upgrading. JPMorgan initiated a Neutral at $32 in mid-September. Barclays, maintaining Overweight, trimmed to $35 from $39 the day after the print. Needham, the most bullish name on the list at a $42 target, sits well above the pack. The bull case rests on GLP-1 weight-loss demand, a nascent testosterone replacement therapy business management is targeting as a $100 million-plus annual revenue category, and the Eucalyptus international acquisition underpinning a $600 million international revenue guidance line. Bears counter that EV/EBITDA of around 13x sits at a meaningful premium to sub-sector peers, gross margin compressed to 64% as reinvestment accelerates, and regulatory risk around compounded GLP-1s remains an unresolved overhang. On factor scores, earnings momentum is weak, with the 30-day EPS momentum ranked in the 2nd percentile and EPS surprise in the 1st, suggesting recent estimates have moved against the stock.
On the ownership register, Andrew Dudum, the CEO and largest individual holder, carries a Schedule 13D filing, making him an activist-classified holder under SEC rules. His most recent amendment, filed August 31, shows a stake trimmed from 10.3% to 9.4% of class. The institutional data flags the direction of travel: Dudum's holdings in the custody data show a reduction of roughly 1.4 million shares in the most recently reported period. The 10b5-1 plan sales from the CFO and CLO across September, while structured and pre-planned, add to the picture of insiders monetising into strength. The 90-day net insider value across the register is negative $3.7 million. BlackRock added 2.4 million shares in August and now holds 12.3% of shares outstanding, one of the larger institutional positions building even as the CEO reduces. (Activist stakes are as-last-disclosed around the 5% threshold; a holder may fall below that level without filing again.)
Earnings history adds some context for November 2. The most recent print, on August 10, produced a 1-day decline of 3.4% and a 5-day decline of 9.4%, despite the headline revenue beat. The earlier print in August 2026 (Q1) saw a 1-day gain of 15.8% and a 5-day gain of 14.4%, a radically different outcome, so the reaction function is volatile and appears sensitive to whether the guidance walk was net positive or negative. Q3 results in November will be the next test of whether the GLP-1 regulatory environment has clarified, whether the Eucalyptus integration is tracking the $600 million international target, and whether subscriber growth is accelerating fast enough to justify the reinvestment in margin.
What to watch next: the rate at which the short base continues to erode heading into November 2 earnings, and whether the borrow market tightens again if any regulatory development around compounded GLP-1 availability changes the risk calculus for either side.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
